Asli Muvaffak
Head of Biology & Translational Sciences Abundance Biopharma
Asli Muvaffak, PhD, is Head of Biology and Translational Sciences at Abundance Biopharma, where she leads the biological and translational development of GPCR targeted therapies. She has more than 15 years of experience in oncology and drug discovery across biotech and pharma organizations, including GSK, TESARO, ImmunoGen, and Dana-Farber Cancer Institute. Her expertise spans novel target validation through preclinical development across small molecules, antibodies, ADCs, and novel targeted therapeutics.
Seminars
Tuesday 2nd March 2027
Panel Discussion: From AI Adoption to AI Accountability – What Has AI Actually Delivered for GPCR Discovery?
11:00 am
- Where has AI demonstrably delivered measurable impact on GPCR hit identification, optimization and candidate selection?
- What benchmarks and validation frameworks do the field need to credibly assess AI platform performance against traditional methods?
- As AI capabilities expand, where does biological expertise and experimental validation remain non negotiable in the decision-making process?
Wednesday 3rd March 2027
Panel Discussion: Comparing Small Molecules, Peptides & Antibodies to Identify the Optimal Modality for Clinical, Commercial & Patient Success
3:15 pm
- Which modality delivers the greatest advantage across efficacy, safety, tissue penetration and durability, and does the answer depend on the target?
- How much should patient-centric considerations such as dosing frequency, convenience and route of administration influence development decisions?
- When evaluating a new GPCR program, how much does modality choice influence commercial differentiation, partnering opportunities and long-term value creation?
Thursday 4th March 2027
Translating Chemotaxis Biology into Development-Ready GPCR Therapeutics for Autoimmune Disease
3:30 pm
- Leveraging chemotaxis biology to identify GPCR targets capable of delivering more precise immune modulation in autoimmune disease
- Applying modern pharmacology and translational strategies to optimize target coverage, exposure and candidate quality before entering the clinic
- Sharing lessons learned from advancing a GPCR therapeutic through IND-enabling development
